Clinical review report: Brolucizumab (Beovu) (Novartis Pharmaceuticals Canada Inc.) indication : treatment of neovascular (wet) age-related macular degeneration (AMD)
The objective of this review is to perform a systematic review of the beneficial and harmful effects of brolucizumab for the treatment of neovascular age-related macular degeneration. The systematic review protocol for the current review was established prior to the anticipated issuance of the Healt...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, July 2020
|
| Edition: | Version: Final |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references